Vincent O'Neill, Chief Medical Officer at BioXcel Therapeutics, Inc. (BTAI), sold 845 shares at $19.70 ($17K) on 2023-03-15, disclosed to the SEC on 2023-03-16.
Scheduled sale ($17k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BTAI | SELL | 2024-09-17 | $95 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $200 | — | Filing → |
| BTAI | SELL | 2024-04-08 | $432 | — | Filing → |